Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy Meeting Abstract

  

Authors:	Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; Jhaveri, K. L.; Modi, S.; Troso-Sandoval, T. A.; Jack, K.; Ulaner, G.; Jochelson, M. S.; Baselga, J.; Norton, L.; Hudis, C. A.; Dang, C. T.
Abstract Title:	Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
Meeting Title:	53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	15 Suppl.
Meeting Dates:	2017 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-05-20
End Page:	41s
Language:	English
ACCESSION:	WOS:000411895701173
DOI:	10.1200/JCO.2017.35.15_suppl.1037
PROVIDER:	wos
Notes:	Meeting Abstract: 1037 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/147169